Considerations in establishing affinity design goals for development of antibody-based therapeutics

Development of Antibody-Based Therapeutics: Translational Considerations

Volumn 9781441959553, Issue , 2012, Pages 141-151

  Tabrizi, Mohammad ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930151111     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5955-3_6     Document Type: Chapter

References (11)

1. Bornstein GG, Queva C, Tabrizi M, Abbema AV, Chavez C, Wang P et al (2009) Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs. doi:10.1007/s10637-009-9291-z
2. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 12(21-22): 898-910
3. Graff CP, Wittrup KD (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 63(6):1288-1296
4. Moore GL, Chen H, Karki S, Lazar GA (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2(2):181-189
5. Roskos L, Klakamp SL, Liang M, Arends R, Green L (2007) Molecular engineering II: antibody affinity. In: Dubel S (ed) Handbook of therapeutic antibodes. Wiley, pp 149-169
6. Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L (2009a) Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 14(5-6):298-305
7. Tabrizi M, Bornstein GG, Suria H (2009b) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 12:33-43. doi:10.1208/s12248-009-9157-5
8. Tabrizi M, Funelas C, Suria H (2010) Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J 12(4):592-601. doi: 10.1208/s12248-010-9220-2
9. Thurber GM, Zajic SC, Wittrup KD (2007) Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48(6):995-999
10. Thurber GM, Schmidt MM, Wittrup KD (2008a) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29(2):57-61
11. Thurber GM, Schmidt MM, Wittrup KD (2008b) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421-1434